{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:05:41Z","timestamp":1778655941462,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"15-16","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Eosinophilic esophagitis (EoE) is a\u00a0chronic immune-mediated disease of the esophagus with increasing incidence and dysphagia as the main symptom. The management of suspected or known EoE by Austrian endoscopists has not been investigated yet.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A\u00a0web-based survey with 13\u00a0questions about the management of EoE was sent to endoscopists via the Austrian Society of Gastroenterology and Hepatology (\u00d6GGH).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A\u00a0total of 222 endoscopists (74% gastroenterologists, 23% surgeons, and 2% pediatricians; 68% working in a\u00a0hospital) from all 9\u00a0states participated. In patients with dysphagia but a\u00a0normal appearing esophagus, 85% of respondents reported always taking biopsies; however, surgeons were less likely to obtain biopsies compared to gastroenterologists (\u201calways\u201d 69% vs. 90%, \u201csometimes\u201d 29% vs. 10%, \u201cnever\u201d 2% vs. 0%, <jats:italic>p<\/jats:italic>\u202f&lt;\u20090.001). The approved budesonide orodispersible tablet is the preferred first-line drug used in EoE, ahead of proton pump inhibitors (PPI). Only 65% of participants monitor the patients by endoscopy and histology after 12\u00a0weeks of induction therapy, 26% do not continue maintenance therapy, and 22% monitor patients only when symptomatic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The vast majority of Austrian endoscopists adhere to the European and US guidelines in cases of suspected EoE. In contrast, despite the chronic disease course, a\u00a0significant percentage of providers indicate not to use maintenance therapy and monitor the patients routinely.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00508-023-02198-0","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T12:02:54Z","timestamp":1681819374000},"page":"406-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of suspected and known eosinophilic esophagitis\u2014a\u00a0nationwide survey in Austria"],"prefix":"10.1007","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1610-1925","authenticated-orcid":false,"given":"Philipp","family":"Schreiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansj\u00f6rg","family":"Schlager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Madl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Ziachehabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Steidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Dinkhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Reider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Dolak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Peter","family":"Gr\u00f6chenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gottfried","family":"Novacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"issue":"7","key":"2198_CR1","doi-asserted-by":"publisher","first-page":"e14072","DOI":"10.1111\/nmo.14072","volume":"33","author":"WE de Rooij","year":"2021","unstructured":"de Rooij\u00a0WE, Barendsen\u00a0ME, Warners\u00a0MJ, van Rhijn\u00a0BD, Verheij\u00a0J, Bruggink\u00a0AH, et al. Emerging incidence trends of eosinophilic esophagitis over 25\u00a0years: results of a\u00a0nationwide register-based pathology cohort. Neurogastroenterol Motil. 2021;33(7):e14072.","journal-title":"Neurogastroenterol Motil"},{"issue":"6","key":"2198_CR2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1055\/a-0885-1963","volume":"57","author":"S Miehlke","year":"2019","unstructured":"Miehlke\u00a0S, von Arnim\u00a0U, Schlag\u00a0C, Frieling\u00a0T, Madisch\u00a0A, Loibl\u00a0R, et\u00a0al. Clinical management of eosinophilic esophagitis\u2014a\u00a0nationwide survey among gastroenterologists in Germany. Z\u00a0Gastroenterol. 2019;57(6):745\u201352.","journal-title":"Z Gastroenterol"},{"issue":"9","key":"2198_CR3","doi-asserted-by":"publisher","first-page":"doac003","DOI":"10.1093\/dote\/doac003","volume":"35","author":"P Schreiner","year":"2022","unstructured":"Schreiner\u00a0P, Safroneeva\u00a0E, Schoepfer\u00a0A, Greuter\u00a0T, Biedermann\u00a0L, Schlag\u00a0C, et\u00a0al. Management of eosinophilic esophagitis associated food impaction in Europe and the United States. Dis Esophagus. 2022;35(9):doac3. https:\/\/doi.org\/10.1093\/dote\/doac003.","journal-title":"Dis Esophagus"},{"issue":"3","key":"2198_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2050640616689525","volume":"5","author":"AJ Lucendo","year":"2017","unstructured":"Lucendo\u00a0AJ, Molina-Infante\u00a0J, Arias\u00a0A, von Arnim\u00a0U, Bredenoord\u00a0AJ, Bussmann\u00a0C, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol\u00a0J. 2017;5(3):335\u201358.","journal-title":"United European Gastroenterol J"},{"issue":"6","key":"2198_CR5","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","volume":"158","author":"I Hirano","year":"2020","unstructured":"Hirano\u00a0I, Chan\u00a0ES, Rank\u00a0MA, Sharaf\u00a0RN, Stollman\u00a0NH, Stukus\u00a0DR, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776\u201386.","journal-title":"Gastroenterology"},{"issue":"6","key":"2198_CR6","doi-asserted-by":"publisher","first-page":"doy133","DOI":"10.1093\/dote\/doy133","volume":"32","author":"JW Chang","year":"2019","unstructured":"Chang\u00a0JW, Saini\u00a0SD, Mellinger\u00a0JL, Chen\u00a0JW, Zikmund-Fisher\u00a0BJ, Rubenstein\u00a0JH. Management of eosinophilic esophagitis is often discordant with guidelines and not patient-centered: results of a survey of gastroenterologists. Dis Esophagus. 2019;32(6):doy133. https:\/\/doi.org\/10.1093\/dote\/doy133.","journal-title":"Dis Esophagus"},{"issue":"1","key":"2198_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MPG.0000000000001909","volume":"67","author":"E Zifman","year":"2018","unstructured":"Zifman\u00a0E, Banai\u00a0H, Shamir\u00a0R, Ringel-Kulka\u00a0T, Zevit\u00a0N. Practice differences in the diagnosis and management of eosinophilic esophagitis among adult and pediatric gastroenterologists in Israel. J\u00a0Pediatr Gastroenterol Nutr. 2018;67(1):34\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"11","key":"2198_CR8","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.14309\/ajg.0000000000001950","volume":"117","author":"FR Murray","year":"2022","unstructured":"Murray\u00a0FR, Kreienbuehl\u00a0AS, Greuter\u00a0T, Nennstiel\u00a0S, Safroneeva\u00a0E, Saner\u00a0C, et\u00a0al. Diagnostic delay in patients with eosinophilic esophagitis has not changed since the first description 30 years ago: diagnostic delay in eosinophilic esophagitis. Am J Gastroenterol. 2022;117(11):1772\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2198_CR9","first-page":"1459","volume":"71","author":"A Dhar","year":"2022","unstructured":"Dhar\u00a0A, Haboubi\u00a0HN, Attwood\u00a0SE, Auth\u00a0MKH, Dunn\u00a0JM, Sweis\u00a0R, et\u00a0al. British society of gastroenterology (BSG) and British society of paediatric gastroenterology, hepatology and nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022;71(8):1459\u201387.","journal-title":"Gut"},{"issue":"12","key":"2198_CR10","doi-asserted-by":"publisher","first-page":"doz056","DOI":"10.1093\/dote\/doz056","volume":"32","author":"JW Chang","year":"2019","unstructured":"Chang\u00a0JW, Olson\u00a0S, Kim\u00a0JY, Dolan\u00a0R, Greenson\u00a0J, Sanders\u00a0G, et al. Loss to follow-up after food impaction among patients with and without eosinophilic esophagitis. Dis Esophagus. 2019;32(12):doz56. https:\/\/doi.org\/10.1093\/dote\/doz056.","journal-title":"Dis Esophagus"},{"key":"2198_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.07.007","author":"FR Murray","year":"2022","unstructured":"Murray\u00a0FR, Kreienbuhl\u00a0A, Straumann\u00a0A, Biedermann\u00a0L, Schreiner\u00a0P. Natural history of patients lost to follow-up after esophageal food impaction. Clin Gastroenterol Hepatol. 2022; https:\/\/doi.org\/10.1016\/j.cgh.2022.07.007.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"2198_CR12","doi-asserted-by":"publisher","first-page":"doab030","DOI":"10.1093\/dote\/doab030","volume":"34","author":"L Hillman","year":"2021","unstructured":"Hillman\u00a0L, Donohue\u00a0S, Broman\u00a0AT, Hoversten\u00a0P, Gaumnitz\u00a0E, Lomeli\u00a0L. Empiric proton pump inhibitor therapy after esophageal food impaction may mask eosinophilic esophagitis diagnosis at follow-up. Dis Esophagus. 2021;34(11):doab30. https:\/\/doi.org\/10.1093\/dote\/doab030.","journal-title":"Dis Esophagus"},{"issue":"13","key":"2198_CR13","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/j.cgh.2020.01.024","volume":"18","author":"EJ Laserna-Mendieta","year":"2020","unstructured":"Laserna-Mendieta\u00a0EJ, Casabona\u00a0S, Savarino\u00a0E, Perello\u00a0A, Perez-Martinez\u00a0I, Guagnozzi\u00a0D, et al. Efficacy of therapy for eosinophilic esophagitis in real-world practice. Clin Gastroenterol Hepatol. 2020;18(13):2903\u201311.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2198_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","volume":"157","author":"AJ Lucendo","year":"2019","unstructured":"Lucendo\u00a0AJ, Miehlke\u00a0S, Schlag\u00a0C, Vieth\u00a0M, von Arnim\u00a0U, Molina-Infante\u00a0J, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a\u00a0randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74\u201386.e15.","journal-title":"Gastroenterology"},{"issue":"5","key":"2198_CR15","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","volume":"159","author":"A Straumann","year":"2020","unstructured":"Straumann\u00a0A, Lucendo\u00a0AJ, Miehlke\u00a0S, Vieth\u00a0M, Schlag\u00a0C, Biedermann\u00a0L, et al. Budesonide orodispersible tablets maintain remission in a\u00a0randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159(5):1672\u201385.e5.","journal-title":"Gastroenterology"},{"issue":"3","key":"2198_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.gastro.2015.11.004","volume":"150","author":"E Safroneeva","year":"2016","unstructured":"Safroneeva\u00a0E, Straumann\u00a0A, Coslovsky\u00a0M, Zwahlen\u00a0M, Kuehni\u00a0CE, Panczak\u00a0R, et\u00a0al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150(3):581\u201390.e4.","journal-title":"Gastroenterology"},{"issue":"10","key":"2198_CR17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/ajg.2017.202","volume":"112","author":"T Greuter","year":"2017","unstructured":"Greuter\u00a0T, Bussmann\u00a0C, Safroneeva\u00a0E, Schoepfer\u00a0AM, Biedermann\u00a0L, Vavricka\u00a0SR, et al. Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a\u00a0therapeutic concept. Am J Gastroenterol. 2017;112(10):1527\u201335.","journal-title":"Am J Gastroenterol"},{"key":"2198_CR18","volume-title":"Budesonide orodispersible tablets are able to maintain clinical, histological and endoscopic remission in adult patients with eosinophilic esophagitis: results from the 96-weeks open-label extension phase following the 1-year double-blind EOS-2 trial","author":"L Biederman","year":"2022","unstructured":"Biederman\u00a0L. Budesonide orodispersible tablets are able to maintain clinical, histological and endoscopic remission in adult patients with eosinophilic esophagitis: results from the 96-weeks open-label extension phase following the 1\u2011year double-blind EOS\u20112 trial. 2022."},{"issue":"12","key":"2198_CR19","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1016\/j.cgh.2020.08.027","volume":"19","author":"T Greuter","year":"2021","unstructured":"Greuter\u00a0T, Godat\u00a0A, Ringel\u00a0A, Almonte\u00a0HS, Schupack\u00a0D, Mendoza\u00a0G, et al. Effectiveness and safety of high\u2014vs low-dose swallowed topical steroids for maintenance treatment of eosinophilic esophagitis: a multicenter observational study. Clin Gastroenterol Hepatol. 2021;19(12):2514\u201323.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2198_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ueg2.12216","volume":"10","author":"L Bon","year":"2022","unstructured":"Bon\u00a0L, Safroneeva\u00a0E, Bussmann\u00a0C, Biedermann\u00a0L, Schreiner\u00a0P, Vavricka\u00a0SR, et al. Close follow-up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long-term management of eosinophilic esophagitis. United European Gastroenterol\u00a0J. 2022;10(3):308\u201318.","journal-title":"United European Gastroenterol J"},{"issue":"8","key":"2198_CR21","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cgh.2021.10.028","volume":"20","author":"NC Chang","year":"2022","unstructured":"Chang\u00a0NC, Thakkar\u00a0KP, Ketchem\u00a0CJ, Eluri\u00a0S, Reed\u00a0CC, Dellon\u00a0ES. A gap in care leads to progression of fibrosis in eosinophilic esophagitis patients. Clin Gastroenterol Hepatol. 2022;20(8):1701\u20138.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2198_CR22","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002138","author":"DA Leiman","year":"2023","unstructured":"Leiman\u00a0DA, Kamal\u00a0AN, Otaki\u00a0F, Bredenoord\u00a0AJ, Dellon\u00a0ES, Falk\u00a0GW, et\u00a0al. Quality indicators for the diagnosis and management of eosinophilic esophagitis. Am J Gastroenterol. 2023; https:\/\/doi.org\/10.14309\/ajg.0000000000002138.","journal-title":"Am J Gastroenterol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02198-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:36:30Z","timestamp":1692693390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02198-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":22,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2198"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02198-0","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"28 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.\u00a0Schreiner received consulting fees from Falk Pharma, Sanofi, Galapagos, Pfizer, Takeda, Abbvie, Janssen-Cilag and Ferring. H.\u00a0Schlager received consulting fees from Falk Pharma and MedTronic. G.\u00a0Novacek has received consulting fees from AbbVie, MSD, Takeda, Janssen, Sandoz, Pfizer, Astro Pharma, Falk Pharma, Ferring, Gilead, Galapagos and Vifor. L.\u00a0Balcar, C.\u00a0Madl, A.\u00a0Ziachehabi, M.\u00a0Mader, K.\u00a0Steidl, P.\u00a0Dinkhauser, S.\u00a0Reider, W.\u00a0Dolak, C.\u00a0Dejaco, and H.\u00a0P.\u00a0Gr\u00f6chenig declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}